Eric J. Hyllengren Sells 1,364 Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CFO Eric J. Hyllengren sold 1,364 shares of the business’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $11.20, for a total transaction of $15,276.80. Following the completion of the sale, the chief financial officer now owns 23,392 shares in the company, valued at approximately $261,990.40. This trade represents a 5.51 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Atara Biotherapeutics Stock Performance

Shares of Atara Biotherapeutics stock opened at $11.47 on Friday. The firm has a market cap of $66.07 million, a P/E ratio of -0.44 and a beta of 0.50. The firm’s 50-day simple moving average is $9.19 and its 200-day simple moving average is $10.11. Atara Biotherapeutics, Inc. has a twelve month low of $6.50 and a twelve month high of $39.50.

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) EPS for the quarter, beating analysts’ consensus estimates of ($3.77) by $0.84. The firm had revenue of $40.19 million during the quarter, compared to analyst estimates of $23.00 million. During the same quarter last year, the firm earned ($16.50) earnings per share. On average, equities analysts forecast that Atara Biotherapeutics, Inc. will post -12.12 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on ATRA shares. HC Wainwright reissued a “neutral” rating on shares of Atara Biotherapeutics in a research note on Wednesday, August 21st. Canaccord Genuity Group lifted their price target on Atara Biotherapeutics from $13.00 to $21.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Finally, Mizuho upgraded Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and decreased their price objective for the stock from $25.00 to $18.00 in a research report on Friday, August 16th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, Atara Biotherapeutics presently has a consensus rating of “Hold” and an average price target of $16.67.

Institutional Investors Weigh In On Atara Biotherapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Delap Wealth Advisory LLC acquired a new stake in shares of Atara Biotherapeutics during the 1st quarter worth approximately $29,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Atara Biotherapeutics during the 2nd quarter valued at $53,000. Cubist Systematic Strategies LLC acquired a new position in shares of Atara Biotherapeutics in the 2nd quarter valued at $79,000. State Street Corp boosted its position in shares of Atara Biotherapeutics by 52.3% in the 3rd quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock worth $182,000 after purchasing an additional 7,680 shares during the last quarter. Finally, FMR LLC grew its stake in shares of Atara Biotherapeutics by 41.7% during the third quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock worth $204,000 after purchasing an additional 7,381 shares during the period. Institutional investors and hedge funds own 70.90% of the company’s stock.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.